Alnylam Pharmaceuticals Inc.

Products

Category

Product

Brand

Description

RNAi Technologies and Global Markets (BIO127C)

Onpattro (patisiran)		FDA approved patisiran in 2018, for the treatment of the polyneuropathy of hereditary, transthyretin-mediated amyloidosis or hATTR amyloidosis in adults.
Givlaari (givosiran)		FDA approved givosiran in 2019, for the treatment of adults with acute hepatic porphyria, or AHP. In EU it is approved for the treatment of AHP in adults and adolescents aged 12 years and older.
Oxlumo (lumasiran)		FDA approved lumasiran in 2020, for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment